NCT03037554

Brief Summary

A home-based, sham-controlled, double-blind, crossover study evaluating the effects of wearing sleepwear with lateralized thermal characteristics on subjective and objective sleep measures, proximal skin temperature, and sternal skin moisture in menopausal women complaining of sleep disturbance and vasomotor symptoms.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
4

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started May 2017

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 19, 2017

Completed
12 days until next milestone

First Posted

Study publicly available on registry

January 31, 2017

Completed
4 months until next milestone

Study Start

First participant enrolled

May 21, 2017

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 15, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 15, 2020

Completed
Last Updated

April 1, 2021

Status Verified

March 1, 2021

Enrollment Period

2.8 years

First QC Date

January 19, 2017

Last Update Submit

March 26, 2021

Conditions

Keywords

Skin TemperatureHot FlashesSleep Disturbance

Outcome Measures

Primary Outcomes (3)

  • Total Sleep Time

    Minutes of sleep of any stage, as scored by conventional criteria, across recording period.

    Two nights in the experimental condition and two nights in the control condition.

  • Wakefulness After Sleep Onset

    Minutes of Wakefulness, as scored by conventional criteria, from first epoch of sleep until end of recording period.

    Two nights in the experimental condition and two nights in the control condition.

  • Minutes of non-rapid eye movement (NREM) Stage 1 Sleep

    Minutes of NREM Stage 1 Sleep, as scored by conventional criteria, across recording period.

    Two nights in the experimental condition and two nights in the control condition.

Secondary Outcomes (1)

  • Proximal Skin Temperature

    Measurements taken every 90 seconds across two-night experimental and control conditions

Other Outcomes (2)

  • Position Monitoring

    Position sampled every two seconds across two nights in experimental condition and two nights in control condition

  • Sternal Skin Moisture

    Measurements taken every three minutes across two nights in experimental condition and two nights in control condition

Study Arms (2)

Lateralized Thermal Sleepwear

EXPERIMENTAL

For two consecutive nights subjects will wear Sleepwear with Lateralized Thermal Characteristics

Device: Sleepwear with Lateralized Thermal Characteristics

Sham-Lateralized Sleepwear

SHAM COMPARATOR

For two consecutive nights subjects will wear Sham-Lateralized Sleepwear

Device: Sham-Lateralized Sleepwear

Interventions

Subjects will wear sleepwear constructed with insulating fabric on one side and conductive fabric on the other side, arranged bilaterally.

Lateralized Thermal Sleepwear

Subjects will wear sleepwear constructed with two insulating fabrics arranged bilaterally.

Sham-Lateralized Sleepwear

Eligibility Criteria

Age40 Years - 69 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • At least 12 months since last menstrual period
  • Subjective complaint of sleep disturbance, confirmed by Pittsburgh Sleep Quality Index score greater than 5
  • Subjective complaint of at least moderate symptoms of menopause, confirmed by modified Kupperman score greater than 15
  • Ability to sleep in the left lateral, right lateral and supine positions

You may not qualify if:

  • Unable to taper off, with health care provider's agreement, hypnotic or sedative medications, hormone replacement therapy, clonidine, gabapentin, or isoflavones and other botanical compounds used to treat vasomotor symptoms of menopause
  • Unable to taper to two or fewer caffeinated beverages per day
  • Unable to taper to one or fewer alcoholic beverages per day
  • Unable to taper off nicotine in any form
  • Unable to taper off recreational drugs
  • Subjective sleep, based on two-week sleep logs, averaging less than 4.0 or greater than 7.5 hours per night
  • Clinical suspicion of obstructive sleep apnea, periodic leg movements or other significant physiological sleep disturbance
  • Known skin allergy to silver, cotton, nylon, surgical tape and other adhesives

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St. Peter's Sleep Center

Albany, New York, 12205, United States

Location

MeSH Terms

Conditions

Hot FlashesParasomnias

Condition Hierarchy (Ancestors)

Signs and SymptomsPathological Conditions, Signs and SymptomsSleep Wake DisordersNervous System DiseasesMental Disorders

Study Officials

  • Paul Glovinsky, Ph.D.

    St. Peter's Sleep Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR
Masking Details
Treatment and sham-control sleepwear will be allocated to subjects in a counterbalanced manner by a study administrator who will not otherwise interact with subjects.
Purpose
TREATMENT
Intervention Model
CROSSOVER
Model Details: Hierarchical linear model evaluating repeated measures nested within subjects
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Director, St. Peter's Sleep Center

Study Record Dates

First Submitted

January 19, 2017

First Posted

January 31, 2017

Study Start

May 21, 2017

Primary Completion

March 15, 2020

Study Completion

March 15, 2020

Last Updated

April 1, 2021

Record last verified: 2021-03

Data Sharing

IPD Sharing
Will not share

Locations